William F. Hahne
Corporate Officer/Principal chez BIO-PATH HOLDINGS, INC.
Postes actifs de William F. Hahne
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BIO-PATH HOLDINGS, INC. | Corporate Officer/Principal | - | - |
| Chief Tech/Sci/R&D Officer | 17/04/2017 | - |
Historique de carrière de William F. Hahne
Anciens postes connus de William F. Hahne
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMUNON, INC. | Chief Tech/Sci/R&D Officer | 01/01/2006 | 01/12/2007 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | 01/01/2003 | 01/01/2005 |
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Chief Tech/Sci/R&D Officer | 01/01/1997 | 01/01/2002 |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Chief Tech/Sci/R&D Officer | 01/02/2008 | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | - | - |
Formation de William F. Hahne
| Grinnell College | Undergraduate Degree |
| Cornell University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 6 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 6 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IMUNON, INC. | Health Technology |
| BIO-PATH HOLDINGS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
- Bourse
- Insiders
- William F. Hahne
- Expérience
